Agostino G.
- Country
- Italy
- Department
- UOC Malattie del Metabolismo
Research Overview
- Exposure-Response Study of Siplizumab in Adults with New Onset Type 1 Diabetes: A 12-Month, Randomized, Single-Blind, Placebo-Controlled Trial
- J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
Data & Insights
Has run more than one trial at 4 of 100 partner sites.
Specializations
Diabetes Management
This investigator specializes in both Type 1 and Type 2 diabetes treatment approaches, with particular emphasis on newly diagnosed cases and metabolic control strategies.
- New onset Type 1 diabetes interventions
- Beta-cell function preservation
- Glycemic control optimization
Their research encompasses innovative therapeutic approaches for diabetes management across different patient populations.
Metabolic Disorders
The investigator focuses on the treatment of obesity and metabolic conditions, particularly in relation to diabetes complications.
- Obesity management in diabetic patients
- Weight control interventions
- Metabolic syndrome treatment
Their work addresses the complex relationship between weight management and diabetic conditions.
Cardiovascular Health
The investigator's expertise extends to cardiovascular risk management in patients with metabolic disorders, including diabetes-related complications.
- Cardiovascular risk assessment
- Chronic kidney disease management
- Cardiometabolic health optimization
Their research integrates cardiovascular care with diabetes and obesity treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.